Alliance A071701 (Brain Metastases)

Purpose of this Study

We are doing this study to learn more about the side effects of the study drug and to determine if it will help shrink the cancer by at least 30%.

Who Can Participate?

Eligibility

Adults who are diagnosed with brain metastases.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will:
  • Have blood draws
  • Have EKG's (a way to measure your heart activity)
  • Take 1 of the 3 study drugs that is assigned to your specific cancer
  • Keep a pill diary (to help track when you take your pills)
*The 3 types of medication are Abemaciclib, GDC-0084, and Entrectinib

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

Yes

Study Details

Full Title

Alliance A071701: Genomically-Guided Treatment Trial in Brain Metastases

Principal Investigator

Carey
Anders

Protocol Number

PRO00104080

NCT ID

NCT03994796

Phase

II

Enrollment Status

Open to Enrollment